PharmaMark
A pre-publication review workspace for healthcare marketing teams that links each claim to governing-source candidates, supporting evidence, named reviewers, approved alternatives, and a bounded decision receipt.
Healthcare brands publish claims across web pages, email, social posts, decks, and campaign assets while FDA, FTC, CMS, privacy, and internal policies overlap. Existing monitoring validates demand, but a scanner result cannot determine legal applicability, prove substantiation, or authorize publication. PharmaMark moves review into the publishing workflow: it inventories claims, finds rule and precedent candidates, binds evidence, routes qualified review, and records a versioned decision. The receipt proves only what was reviewed, by whom, under which scope and evidence; it is not regulatory clearance or a shield from enforcement.
The regulatory, legal, medical, quality, or marketing-operations owner responsible for reviewing healthcare campaign claims before publication, with channel owners and external agencies as contributors.
A March 2026 launch and reported 73% warning-letter increase create a recent trigger.
The product must accelerate publication while making uncertainty and escalation more visible, not disguising them as clearance.
One cross-reference and one inbound signal support the direction but do not establish broad convergence.
A reported enforcement increase, a newly launched enterprise platform, recurring multi-channel review, and a specific pre-publication evidence workflow create a timely mid-market direction.
Only one cross-reference is supplied, three integrations remain unverified, the barrier that newly broke is not proven, and qualified healthcare advertising review cannot be automated into a safe-or-forbidden answer.
Discussion
No comments yet — be the first to weigh in.